Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISAL 2019 | Hellstrand lab leukemia research: exploring immune escape and defining therapeutic targets

Kristoffer Hellstrand • 14 Mar 2019
ISAL 2019
Acute Myeloid Leukemia Leukemia

Kristoffer Hellstrand, MD, PhD, discusses his group’s aims and ongoing work at Sahlgrenska Cancer Center, University of Gothenburg, Gothenburg, Sweden, which includes both basic research and the clinical development of agents. Prof. Hellstrand also discusses a recent publication from his group on how HLA-B-21 dimorphism impacts NK-cell function and the clinical outcome of immunotherapy in acute myeloid leukemia (AML).

More from Kristoffer Hellstrand

3:43
Histamine dihydrochloride to prevent relapse in AML: development and ongoing research
Kristoffer Hellstrand • 1 Mar 2019
1:22
The importance of finding strategies to prevent relapse of acute myeloid leukemia (AML)
Kristoffer Hellstrand • 19 Feb 2017
1:17
Remission maintenance with histamine dihydrochloride (HDC)/IL-2 therapy in AML
Kristoffer Hellstrand • 19 Feb 2017

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals